NASDAQ:IMMP

Immutep Stock Insider Trading

etoro logo Buy IMMP
*Your capital is at risk
$0.377
+0.0030 (+0.80%)
At Close: Jun 22, 2026

Immutep Stock Insider Power

Based on the 19 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 4.8M and sold 0 IMMP shares in the last 19 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 19 transactions)
0
Buy 4.8M shares
Sell 0 shares
100% Buy Activity
Negligible or No Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Dec 01, 2029
Buy
Performance rights (right to receive)
Meyers Pete A.
Director
Director 650 000
Value: $0
Dec 01, 2028
Buy
Performance rights (right to receive)
Boyce Elisabeth Amanda
Director
Director 295 985
Value: $0
Dec 01, 2028
Buy
Performance rights (right to receive)
Voigt Marc
See Remarks
Officer 1 200 000
Value: $0
Dec 01, 2028
Buy
Performance rights (right to receive)
Miller Deanne Diem
Chief Operating Officer
C-Suite Officer 600 000
Value: $0
Dec 01, 2028
Buy
Performance rights (right to receive)
Winckels Stephan Karel Gerard
Chief Medical Officer
Officer 221 708
Value: $0
Dec 01, 2028
Buy
Performance rights (right to receive)
Triebel Frederic Joseph Daniel
Director
Director 900 000
Value: $0
Dec 01, 2028
Buy
Performance rights (right to receive)
Howard Russell J
Director
Director 461 746
Value: $0
Dec 01, 2028
Buy
Performance rights (right to receive)
Mueller Christian
Chief Development Officer
Officer 466 666
Value: $0
Mar 18, 2026
Buy
Ordinary Shares
Boyce Elisabeth Amanda
Director
Director 0
Value: $0
Mar 18, 2026
Buy
Ordinary Shares
Voigt Marc
See Remarks
Officer 0
Value: $0
Mar 18, 2026
Buy
Ordinary Shares
Voigt Marc
See Remarks
Officer 0
Value: $0
Mar 18, 2026
Buy
Ordinary Shares
Voigt Marc
See Remarks
Officer 0
Value: $0
Mar 18, 2026
Buy
Ordinary Shares
Miller Deanne Diem
Chief Operating Officer
C-Suite Officer 0
Value: $0
Mar 18, 2026
Buy
Ordinary Shares
Meyers Pete A.
Director
Director 0
Value: $0
Mar 18, 2026
Buy
Ordinary Shares
Winckels Stephan Karel Gerard
Chief Medical Officer
Officer 0
Value: $0
Mar 18, 2026
Buy
Ordinary Shares
Triebel Frederic Joseph Daniel
Director
Director 0
Value: $0
Mar 18, 2026
Buy
Ordinary Shares
Triebel Frederic Joseph Daniel
Director
Director 0
Value: $0
Mar 18, 2026
Buy
Ordinary Shares
Howard Russell J
Director
Director 0
Value: $0
Mar 18, 2026
Buy
Ordinary Shares
Mueller Christian
Chief Development Officer
Officer 0
Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT IMMUTEP LTD
Immutep
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, wh...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
18.12% Jun 12
DHI
$146.71
6.29% Jun 10
PHM
$118.49
6.02% Jun 10
EAT
$140.46
17.09% Jun 05
E
ETD
$20.67
3.19% Jun 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE